[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 21 of about 21
1. Greenberg HS, Chamberlain MC, Glantz MJ, Wang S: Adult medulloblastoma: multiagent chemotherapy. Neuro Oncol; 2001 01;3(1):29-34
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Adult medulloblastoma: multiagent chemotherapy.
  • In this study, the records of 17 adult patients with medulloblastoma treated with craniospinal radiation and 1 of 2 multiagent chemotherapy protocols were reviewed for progression-free survival, overall survival, and toxicity, and the patients were compared with each other and with similarly treated children and adults.
  • Seventeen medulloblastoma patients (11 female, 6 male) with a median age of 23 years (range, 18-47 years) were treated with surgery, craniospinal radiation (CSRT) plus local boost, and 1 of 2 adjuvant chemotherapy regimens.
  • All tumors were infratentorial (10 in 4th ventricle and 7 in left or right hemisphere).
  • Two patients relapsed during chemotherapy and 6 relapsed after completing all therapy at 18, 18, 26, 30, 40, and 48 months.
  • Toxicity during the Packer protocol was moderately severe, with only 1 of 10 patients able to complete all therapy.
  • Two patients had severe abdominal pain during CSRT + vincristine, and 5 had peripheral neuropathy during vincristine therapy.
  • To know whether adding adjuvant chemotherapy to craniospinal radiation in adult therapy increases relapse-free and overall survival, we must await the results of a larger randomized controlled clinical trial.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Infratentorial Neoplasms / drug therapy. Medulloblastoma / drug therapy
  • [MeSH-minor] Abdominal Pain / chemically induced. Adolescent. Adult. Cerebrospinal Fluid Shunts. Chemotherapy, Adjuvant. Cisplatin / administration & dosage. Cisplatin / adverse effects. Combined Modality Therapy. Cranial Irradiation. Cyclophosphamide / administration & dosage. Cyclophosphamide / adverse effects. Disease-Free Survival. Etoposide / administration & dosage. Etoposide / adverse effects. Female. Gastrointestinal Diseases / chemically induced. Hearing Loss, Sensorineural / chemically induced. Hematologic Diseases / chemically induced. Humans. Life Tables. Lomustine / administration & dosage. Lomustine / adverse effects. Male. Neoplasm Invasiveness. Neoplasm Recurrence, Local. Peripheral Nervous System Diseases / chemically induced. Radiotherapy, Adjuvant. Retrospective Studies. Survival Analysis. Vincristine / administration & dosage. Vincristine / adverse effects

  • Genetic Alliance. consumer health - Medulloblastoma.
  • Hazardous Substances Data Bank. LOMUSTINE .
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11305414.001).
  • [ISSN] 1522-8517
  • [Journal-full-title] Neuro-oncology
  • [ISO-abbreviation] Neuro-oncology
  • [Language] eng
  • [Publication-type] Comparative Study; Evaluation Studies; Journal Article; Review
  • [Publication-country] England
  • [Chemical-registry-number] 5J49Q6B70F / Vincristine; 6PLQ3CP4P3 / Etoposide; 7BRF0Z81KG / Lomustine; 8N3DW7272P / Cyclophosphamide; Q20Q21Q62J / Cisplatin
  • [Number-of-references] 15
  • [Other-IDs] NLM/ PMC1920599
  •  go-up   go-down


2. Tsugu H, Oshiro S, Ueno Y, Abe H, Komatsu F, Sakamoto S, Matsumoto S, Nabeshima K, Fukushima T, Inoue T: Primary yolk sac tumor within the lateral ventricle. Neurol Med Chir (Tokyo); 2009 Nov;49(11):528-31
Genetic Alliance. consumer health - Yolk sac tumor.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary yolk sac tumor within the lateral ventricle.
  • A 13-year-old girl presented with an exceedingly rare case of primary yolk sac tumor located within the lateral ventricle, manifesting as headache, nausea, and diplopia.
  • Magnetic resonance imaging revealed a 4-cm-diameter solid enhanced mass within the left inferior horn of the lateral ventricle.
  • The tumor was removed subtotally via left middle temporal corticotomy.
  • The histological and immunohistochemical diagnosis was pure yolk sac tumor.
  • The patient underwent radiotherapy (whole brain, 30 Gy; tumor bed, 21 Gy; whole spinal axis, 30 Gy) and chemotherapy (ifosfamide, cisplatin, etoposide).
  • After three treatment cycles, the serum AFP level had decreased to 4.5 ng/ml.
  • However, the tumor recurred with cerebrospinal fluid dissemination after nine cycles of chemotherapy.
  • [MeSH-major] Brain / pathology. Cerebral Ventricle Neoplasms / diagnosis. Endodermal Sinus Tumor / diagnosis. Lateral Ventricles / pathology
  • [MeSH-minor] Adolescent. Biomarkers, Tumor / analysis. Biomarkers, Tumor / blood. Chorionic Gonadotropin, beta Subunit, Human / blood. Diplopia / etiology. Drug Therapy. Fatal Outcome. Female. Headache / etiology. Humans. Hydrocephalus / etiology. Intracranial Hypertension / etiology. Magnetic Resonance Imaging. Nausea / etiology. Neoplasm Metastasis. Neoplasm Recurrence, Local. Neurosurgical Procedures. Radiotherapy. Ventriculostomy. alpha-Fetoproteins / metabolism

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19940403.001).
  • [ISSN] 1349-8029
  • [Journal-full-title] Neurologia medico-chirurgica
  • [ISO-abbreviation] Neurol. Med. Chir. (Tokyo)
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Chorionic Gonadotropin, beta Subunit, Human; 0 / alpha-Fetoproteins
  •  go-up   go-down


3. Ogimoto A, Hamada M, Ohtsuka T, Hara Y, Shigematsu Y, Yokoyama A, Imagawa H, Kawachi K, Kito K, Higaki J: Rapid progression of primary cardiac leiomyosarcoma with obstruction of the left ventricular outflow tract and mitral stenosis. Intern Med; 2003 Sep;42(9):827-30
MedlinePlus Health Information. consumer health - Atrial Fibrillation.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Rapid progression of primary cardiac leiomyosarcoma with obstruction of the left ventricular outflow tract and mitral stenosis.
  • We report a 73-year-old woman with primary cardiac leiomyosarcoma in the left atrium and ventricle.
  • Obstruction of the left ventricular outflow tract and mitral stenosis were induced by the tumor.
  • She refused postoperative chemotherapy and radiotherapy, and died suddenly at home 89 days after surgery.
  • To our knowledge, this is the first observation of mitral stenosis concomitant with obstruction of the left ventricular outflow tract in a patient with primary cardiac leiomyosarcoma.
  • [MeSH-minor] Aged. Cardiac Surgical Procedures / methods. Echocardiography. Fatal Outcome. Female. Humans. Neoplasm Invasiveness. Tomography, X-Ray Computed. Treatment Refusal

  • Genetic Alliance. consumer health - Leiomyosarcoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 14518670.001).
  • [ISSN] 0918-2918
  • [Journal-full-title] Internal medicine (Tokyo, Japan)
  • [ISO-abbreviation] Intern. Med.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


Advertisement
4. Chughtai A, Cronin P, Lucas DR, Prager R, Kazerooni EA: Metastatic shoulder liposarcoma to the right ventricle: CT findings. J Thorac Imaging; 2007 May;22(2):195-8
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Metastatic shoulder liposarcoma to the right ventricle: CT findings.
  • A right ventricular liposarcoma metastasis is described in a 46-year-old man, who was admitted with significant shortness of breath and fatigue, and in whom a large lobulated low attenuation mass occupying most of the right ventricular cavity, with extension through the right ventricular apex and a small-to-moderate pericardial effusion was detected by electrocardiogram-gated cardiac computed tomography.
  • The patient had an antecedent history of a left upper arm liposarcoma treated with surgical resection, chemotherapy, and postoperative radiotherapy 3 years earlier.
  • Surgical resection was performed with the majority of the neoplasm removed though; the right ventricular apex and epicardial extension of tumor could not be fully resected.
  • The histopathologic analysis revealed a liposarcoma, similar to the one resected in the left arm 3 years earlier.
  • Electrocardiogram-gated cardiac computed tomography was able to visualize the metastatic tumor within the heart, accurately evaluate cardiac function and allow for prompt surgical treatment that produced relief of symptoms, and assess for further metastatic disease within the thorax.
  • [MeSH-major] Bone Neoplasms / pathology. Heart Neoplasms / diagnosis. Heart Neoplasms / secondary. Liposarcoma / diagnosis. Shoulder / pathology. Tomography, X-Ray Computed / methods

  • Genetic Alliance. consumer health - Liposarcoma.
  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • MedlinePlus Health Information. consumer health - CT Scans.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17527130.001).
  • [ISSN] 0883-5993
  • [Journal-full-title] Journal of thoracic imaging
  • [ISO-abbreviation] J Thorac Imaging
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Contrast Media; 4419T9MX03 / Iohexol
  •  go-up   go-down


5. Richert MM, Phadke PA, Matters G, DiGirolamo DJ, Washington S, Demers LM, Bond JS, Manni A, Welch DR: Metastasis of hormone-independent breast cancer to lung and bone is decreased by alpha-difluoromethylornithine treatment. Breast Cancer Res; 2005;7(5):R819-27
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Metastasis of hormone-independent breast cancer to lung and bone is decreased by alpha-difluoromethylornithine treatment.
  • INTRODUCTION: Polyamines affect proliferation, differentiation, migration and apoptosis of cells, indicating their potential as a target for cancer chemotherapy.
  • DFMO treatment (2% per orally) began at the day of tumor cell injection or 21 days post injection.
  • DFMO treatment began 7 days prior to injection, or 7 or 14 days post injection.
  • Green fluorescent protein-tagged MDA-MB-435 cells were injected into the left cardiac ventricle in order to assess the incidence and extent of metastasis to the femur.
  • DFMO treatment began 7 days prior to injection.
  • RESULTS: DFMO treatment delayed MDA-MB-231 orthotopic tumor growth to a greater extent than growth of MDA-MB-435 tumors.
  • The most substantial effect on lung colonization by MDA-MB-231 cells occurred when DFMO treatment began 7 days before intravenous injection of tumor cells (incidence decreased 28% and number of metastases per lung decreased 35-40%).
  • When DFMO treatment began 7 days post injection, the incidence and number of metastases decreased less than 10%.
  • Surprisingly, treatment initiated 14 days after tumor cell inoculation resulted in a nearly 50% reduction in the number of lung metastases without diminishing the incidence.
  • After intracardiac injection, DFMO treatment decreased the incidence of bone metastases (55% vs 87%) and the area occupied by the tumor (1.66 mm2 vs 4.51 mm2, P < 0.05).
  • CONCLUSION: Taken together, these data demonstrate that DFMO exerts an anti-metastatic effect in more than one hormone-independent breast cancer, for which no standard form of biologically-based treatment exists.
  • Importantly, the data show that DFMO is effective against metastasis to multiple sites and that treatment is generally more effective when administered early.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Bone Neoplasms / prevention & control. Bone Neoplasms / secondary. Breast Neoplasms / pathology. Eflornithine / therapeutic use. Lung Neoplasms / prevention & control. Lung Neoplasms / secondary. Neoplasm Metastasis / prevention & control

  • Genetic Alliance. consumer health - Lung Cancer.
  • Genetic Alliance. consumer health - Bone Cancer.
  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. Eflornithine .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Int J Cancer. 1997 Jan 17;70(2):175-82 [9009157.001]
  • [Cites] Cancer Lett. 1995 May 25;92(1):49-57 [7757960.001]
  • [Cites] J Natl Cancer Inst. 1997 Sep 3;89(17):1260-70 [9293916.001]
  • [Cites] Cancer. 1997 Oct 15;80(8 Suppl):1572-80 [9362424.001]
  • [Cites] Int J Cancer. 1998 May 18;76(4):563-70 [9590135.001]
  • [Cites] J Natl Cancer Inst. 1998 Aug 19;90(16):1212-8 [9719082.001]
  • [Cites] Clin Cancer Res. 1996 Nov;2(11):1901-6 [9816147.001]
  • [Cites] Clin Cancer Res. 1999 Aug;5(8):2035-41 [10473083.001]
  • [Cites] Clin Exp Metastasis. 2004;21(5):461-7 [15672871.001]
  • [Cites] Cancer Res. 2005 Feb 15;65(4):1146-9 [15734996.001]
  • [Cites] Clin Exp Metastasis. 2005;22(4):331-9 [16170669.001]
  • [Cites] Int J Oncol. 2001 Aug;19(2):317-23 [11445845.001]
  • [Cites] Mol Cell Biol. 2001 Oct;21(19):6549-58 [11533243.001]
  • [Cites] Clin Exp Metastasis. 2002;19(2):95-105 [11964084.001]
  • [Cites] Nat Rev Cancer. 2002 Aug;2(8):584-93 [12154351.001]
  • [Cites] Cancer Cell. 2003 Jun;3(6):537-49 [12842083.001]
  • [Cites] Clin Cancer Res. 2003 Jul;9(7):2769-77 [12855657.001]
  • [Cites] Clin Exp Metastasis. 2003;20(4):321-5 [12856719.001]
  • [Cites] Clin Exp Metastasis. 2003;20(4):327-34 [12856720.001]
  • [Cites] N Engl J Med. 2004 Apr 15;350(16):1655-64 [15084698.001]
  • [Cites] Clin Exp Metastasis. 2004;21(2):119-28 [15168729.001]
  • [Cites] Nat Rev Cancer. 2004 Oct;4(10):781-92 [15510159.001]
  • [Cites] Eur J Biochem. 1986 Apr 1;156(1):31-5 [3082634.001]
  • [Cites] Cancer. 1987 Nov 1;60(9):2237-43 [3440234.001]
  • [Cites] Breast Cancer Res Treat. 1994;32(1):73-84 [7819589.001]
  • [Cites] Clin Exp Metastasis. 1997 May;15(3):272-306 [9174129.001]
  • (PMID = 16168128.001).
  • [ISSN] 1465-542X
  • [Journal-full-title] Breast cancer research : BCR
  • [ISO-abbreviation] Breast Cancer Res.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / R01 CA087728; United States / NIDDK NIH HHS / DK / DK19691; United States / NCI NIH HHS / CA / CA-98237; United States / NCI NIH HHS / CA / CA-87728; United States / NCI NIH HHS / CA / R01 CA098237; United States / NCI NIH HHS / CA / CA-89019; United States / NIDDK NIH HHS / DK / R01 DK019691
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents; ZQN1G5V6SR / Eflornithine
  • [Other-IDs] NLM/ PMC1242150
  •  go-up   go-down


6. Di Valentino M, Menafoglio A, Mazzucchelli L, Siclari F, Gallino A: Rapid-growing left intraventricular cardiac hemangioma. J Am Soc Echocardiogr; 2006 Jul;19(7):939.e5-7
Genetic Alliance. consumer health - Hemangioma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Rapid-growing left intraventricular cardiac hemangioma.
  • A 62 years old man with Child B liver cirrhosis, prostate cancer and a recent colon carcinoma resection was referred to our cardiology department for trans-thoracic-echocardiography (TTE) in order to establish left ventricular function before starting chemotherapy.
  • TTE revealed a mobile mass (16 x 8 mm) attached to the anterior-medial left ventricular wall, protruding and swinging within the left ventricle cavity.
  • [MeSH-minor] Humans. Male. Middle Aged. Neoplasm Invasiveness

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16825010.001).
  • [ISSN] 1097-6795
  • [Journal-full-title] Journal of the American Society of Echocardiography : official publication of the American Society of Echocardiography
  • [ISO-abbreviation] J Am Soc Echocardiogr
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


7. Coelho Neto M, Ramina R, de Meneses MS, Arruda WO, Milano JB: Peritoneal dissemination from central neurocytoma: case report. Arq Neuropsiquiatr; 2003 Dec;61(4):1030-4
Genetic Alliance. consumer health - Central Neurocytoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • CASE: A six years-old boy with recurrent neurocytoma of III ventricle and left thalamus showed fast growth of tumor rest and ascites three and a half years after subtotal removal of the lesion.
  • Chemotherapy was initiated immediately after diagnosis of peritoneal dissemination (etoposide, carboplatin, doxorubicin and cyclophosphamide).
  • The patient developed metabolic imbalance and respiratory failure due to rapid formation of ascitic fluid and died 3 days after the diagnosis of peritoneal dissemination was established.
  • Evaluation of proliferative index may be a guideline parameter for planning adjuvant therapies after surgical treatment in selected cases.
  • [MeSH-major] Cerebral Ventricle Neoplasms / pathology. Neurocytoma / pathology. Peritoneal Neoplasms / secondary
  • [MeSH-minor] Antineoplastic Agents / therapeutic use. Child. Child, Preschool. Fatal Outcome. Humans. Magnetic Resonance Imaging. Male. Neoplasm Invasiveness. Neoplasm, Residual. Peritoneum. Reoperation. Tomography, X-Ray Computed

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 14762613.001).
  • [ISSN] 0004-282X
  • [Journal-full-title] Arquivos de neuro-psiquiatria
  • [ISO-abbreviation] Arq Neuropsiquiatr
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Brazil
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  •  go-up   go-down


8. Weinberg NM, Zwas DR, Owen AN, Zangrilli JG, Van Tassell P: Left ventricular intracardiac metastatic germ cell tumor presenting with hemorrhagic cerebrovascular event. J Am Soc Echocardiogr; 2004 Oct;17(10):1080-3
MedlinePlus Health Information. consumer health - Testicular Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Left ventricular intracardiac metastatic germ cell tumor presenting with hemorrhagic cerebrovascular event.
  • Echocardiography demonstrated testicular cancer metastatic to the septal surface of the left ventricle of the heart with presumed embolization to the cerebrovascular region.
  • The patient received chemotherapy and radiation therapy to the areas of tumor mass with subsequent resolution of tumor burden.
  • This is the first reported case of metastasis from embryonal carcinoma of the testis to the left ventricle of the heart.
  • [MeSH-minor] Adult. Cerebral Hemorrhage / etiology. Diagnosis, Differential. Echocardiography. Humans. Male. Neoplasm Metastasis. Stroke / etiology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15452476.001).
  • [ISSN] 0894-7317
  • [Journal-full-title] Journal of the American Society of Echocardiography : official publication of the American Society of Echocardiography
  • [ISO-abbreviation] J Am Soc Echocardiogr
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


9. Katamadze NA, Lartsuliani KP, Kiknadze MP: Left ventricular function in patients with toxic cardiomyopathy and with idiopathic dilated cardiomyopathy treated with Doxorubicin. Georgian Med News; 2009 Jan;(166):43-8
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Left ventricular function in patients with toxic cardiomyopathy and with idiopathic dilated cardiomyopathy treated with Doxorubicin.
  • Aim of the study was to investigate LV structural and functional parameters in doxorubicin chemotherapy and idiopathic dilated cardiomyopathy as well as to study dynamics of LV systolic-diastolic dysfunction in relation to the increasing doxorubicin dosage.
  • The LV systolic-diastolic function was evaluated twice using echo CG.
  • Doxorubicin cardio toxicity is evident as early as at low total doses (232 mg/m(2)); at a "critical dose" (356-388 mg/m(2)) LV diastolic dysfunction with clinical signs of HF develops; at a total dose of 533 mg/m(2) anthracycline dilated myocardiopathy with LV systolic-diastolic dysfunction and clinical signs of HF develops in 100% of cases.
  • In anthracycline myocardiopathy, LV undergoes the same structural and functional mass index >120 g/m(2) and idiopathic dilated myocardiopathy: LV eccentric hypertrophy (II type LV remodelling with myocardial mass index >120 g/m(2) and relative thickness of LV posterior wall <0.44); decreased LV systolic-diastolic dimensions/volumes; LV diastolic dysfunction of the restrictive type.
  • Etiologic factor is not so important for remodelling of left ventricle, which is the basis of clinically manifested dilated cardiomyopathy.
  • [MeSH-major] Antibiotics, Antineoplastic / adverse effects. Cardiomyopathy, Dilated / chemically induced. Doxorubicin / adverse effects. Heart / drug effects. Hematologic Neoplasms / drug therapy. Stroke Volume / drug effects. Ventricular Function, Left / physiology
  • [MeSH-minor] Adult. Dose-Response Relationship, Drug. Echocardiography. Female. Follow-Up Studies. Humans. Male. Middle Aged. Neoplasm Staging. Prognosis. Risk Factors


10. Kon H, Kumabe T, Jokura H, Shirane R: Recurrent intracranial germinoma outside the initial radiation field with progressive malignant transformation. Acta Neurochir (Wien); 2002 Jun;144(6):611-6
MedlinePlus Health Information. consumer health - Brain Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • A 19-year-old man with a pure germinoma in the pineal region was successfully treated with chemotherapy followed by 24 Gy local irradiation.
  • Near complete response was achieved again after 28.8 Gy whole brain and 24 Gy whole spine irradiation.
  • Enlargement of the recurrent mass at the trigone of the left lateral ventricle was found in spite of additional chemotherapy.
  • The patient died of tumour progression 34 months after the initial treatment.
  • By a combination of chemotherapy regiments in use today, the initial radiation field to treat intracranial germinomas should not be confined to the tumour bed.
  • [MeSH-major] Brain Neoplasms / drug therapy. Brain Neoplasms / radiotherapy. Germinoma / drug therapy. Germinoma / radiotherapy. Neoplasm Recurrence, Local. Pineal Gland / pathology
  • [MeSH-minor] Adult. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Cell Transformation, Neoplastic. Combined Modality Therapy. Disease Progression. Humans. Magnetic Resonance Imaging. Male. Radiosurgery

  • Genetic Alliance. consumer health - Germinoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12111494.001).
  • [ISSN] 0001-6268
  • [Journal-full-title] Acta neurochirurgica
  • [ISO-abbreviation] Acta Neurochir (Wien)
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Austria
  •  go-up   go-down


11. Iyigun T, Ciloglu U, Ariturk C, Civelek A, Tosun R: Recurrent cardiac metastasis of primary femoral osteosarcoma: a case report. Heart Surg Forum; 2010 Oct;13(5):E333-5
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Upon evaluation, a metastatic osteosarcoma in the left ventricle was diagnosed.
  • Based on the collaborative decision of the oncology and cardiovascular surgery clinics, surgery was performed and the patient was discharged without any problems.
  • According to the recommendation of the oncology clinic, chemotherapy was postponed for 6 months after surgery.
  • Based on the collaborative decision, chemotherapy was initiated and in 2 months the size of the recurrent tumors had diminished.
  • The patient is still under the care of the oncology and cardiovascular surgery clinics and continuing her chemotherapy regimen.
  • The location of the metastasis and the characteristics of the primary tumor determine the treatment modality.
  • In some previously published reports, various treatment choices have been described.
  • [MeSH-major] Bone Neoplasms / pathology. Femur. Heart Neoplasms / secondary. Neoplasm Recurrence, Local. Osteosarcoma / secondary
  • [MeSH-minor] Adolescent. Combined Modality Therapy. Diagnosis, Differential. Echocardiography. Female. Follow-Up Studies. Heart Ventricles. Humans. Magnetic Resonance Imaging. Tomography, X-Ray Computed

  • Genetic Alliance. consumer health - Osteosarcoma.
  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20961837.001).
  • [ISSN] 1522-6662
  • [Journal-full-title] The heart surgery forum
  • [ISO-abbreviation] Heart Surg Forum
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


12. Kutsal A, Tansal S, Okutan H, Tuncer I: Primary malignant mesenchymoma of the heart. Eur J Cardiothorac Surg; 2002 Jan;21(1):124-6

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • A case of primary malignant mesenchymoma in a 41-year-old woman arousing from the left atrial septum, obstructing the mitral orifice by passing through it into the left ventricle is described.
  • The tumour was fully resected, and adjuvant chemotherapy was applied, but the patient had died by tumour recurrence in 8 months.
  • [MeSH-minor] Adult. Fatal Outcome. Female. Humans. Neoplasm Recurrence, Local

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11788281.001).
  • [ISSN] 1010-7940
  • [Journal-full-title] European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery
  • [ISO-abbreviation] Eur J Cardiothorac Surg
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  •  go-up   go-down


13. Jenkins DE, Yu SF, Hornig YS, Purchio T, Contag PR: In vivo monitoring of tumor relapse and metastasis using bioluminescent PC-3M-luc-C6 cells in murine models of human prostate cancer. Clin Exp Metastasis; 2003;20(8):745-56
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We used the bioluminescent human prostate carcinoma cell line PC-3M-luc-C6 to non-invasively monitor in vivo growth and response of tumors and metastasis before, during and after treatments.
  • Our goal was to determine the utility of a luciferase-based prostate cancer animal model to specifically assess tumor and metastatic recurrence in vivo following chemotherapy.
  • Cells were also injected into the left ventricle of the heart as an experimental metastasis model.
  • Ex vivo imaging and/or histology was used to confirm and localize metastatic lesions in various tissues initially detected by images in vivo.
  • Our in vivo data detected and quantified early inhibition of subcutaneous and orthotopic prostate tumors in mice as well as significant tumor regrowth post-treatment.
  • Local and distal metastasis was observed within seven days following intracardiac injection of PC-3M-luc-C6 cells.
  • Differential drug responses and metastatic tumor relapse patterns were distinguished over time by in vivo imaging depending on the metastatic site.
  • [MeSH-minor] Animals. Antineoplastic Agents / therapeutic use. Cell Line, Tumor. Disease Models, Animal. Heart Neoplasms / drug therapy. Heart Neoplasms / secondary. Humans. Injections, Subcutaneous. Lung Neoplasms / diet therapy. Lung Neoplasms / secondary. Lymphatic Metastasis. Male. Mice. Mice, Inbred BALB C. Mice, Nude. Neoplasm Recurrence, Local


14. Yokoo H, Kamiya M, Sasaki A, Hirato J, Nakazato Y, Kurachi H: Neurofibromatosis type 1-associated unusual pleomorphic astrocytoma displaying continual malignant progression. Pathol Int; 2001 Jul;51(7):570-7
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Neurofibromatosis type 1-associated unusual pleomorphic astrocytoma displaying continual malignant progression.
  • Patients with neurofibromatosis type 1 (NF1) often have gliomas as a complication, most of which are benign pilocytic astrocytomas which have arisen in optic pathways.
  • In the present case, a 17-year-old girl (at death) with stigmata of NF1, initially had a bulky tumor mass in the left thalamus, developing into the lateral ventricle, at 13 years of age.
  • Partially resected tissue samples showed pleomorphic astrocytoma with abundant xanthoma cells and degenerative structures such as Rosenthal fibers (RF) and eosinophilic granular bodies.
  • Partially resected tumor tissues were composed of monotonous small anaplastic cells with prominent proliferative activity.
  • Postoperative chemotherapy with procarbazine, MCNU and vincristine (PCV) suppressed the residual tumor dramatically, but the regrowing tumor finally became uncontrollable, leading to the patient's death.
  • A review of previously published reports failed to reveal any cases of this type.
  • [MeSH-major] Astrocytoma / pathology. Cerebral Ventricle Neoplasms / pathology. Muscle Proteins. Neurofibromatosis 1 / pathology. Thalamus / pathology
  • [MeSH-minor] Adolescent. Antigens, Nuclear. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Biomarkers, Tumor / analysis. DNA Primers / chemistry. DNA, Neoplasm / analysis. Fatal Outcome. Female. Humans. Microfilament Proteins / analysis. Neoplasm Recurrence, Local. Neoplasms, Second Primary / pathology. Nitrosourea Compounds / therapeutic use. Nuclear Proteins / analysis. Polymerase Chain Reaction. Polymorphism, Single-Stranded Conformational. Procarbazine / therapeutic use. Tumor Suppressor Protein p53 / analysis. Vincristine / therapeutic use

  • Genetic Alliance. consumer health - Neurofibromatosis.
  • Genetic Alliance. consumer health - Neurofibromatosis type 1.
  • Hazardous Substances Data Bank. VINCRISTINE .
  • Hazardous Substances Data Bank. PROCARBAZINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11472572.001).
  • [ISSN] 1320-5463
  • [Journal-full-title] Pathology international
  • [ISO-abbreviation] Pathol. Int.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Australia
  • [Chemical-registry-number] 0 / Antigens, Nuclear; 0 / Biomarkers, Tumor; 0 / DNA Primers; 0 / DNA, Neoplasm; 0 / Microfilament Proteins; 0 / Muscle Proteins; 0 / Nitrosourea Compounds; 0 / Nuclear Proteins; 0 / Tagln protein, mouse; 0 / Tumor Suppressor Protein p53; 35S93Y190K / Procarbazine; 5J49Q6B70F / Vincristine; RYH2T97J77 / ranimustine
  •  go-up   go-down


15. Choi UK, Cha SH, Song GS, Choi CH, Lee SW, Lim YT, Kim WT: Recurrent intracranial germinoma along the endoscopic ventriculostomy tract. Case report. J Neurosurg; 2007 Jul;107(1 Suppl):62-5
MedlinePlus Health Information. consumer health - Endoscopy.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The authors report a case of a recurrent intracranial germinoma along the site of an endoscopic third ventriculostomy (ETV) after complete local tumor control using 3D conformal radiation therapy.
  • A 13-year-old girl presented with sudden left upward gaze limitation for 4 days.
  • An ETV and tumor biopsy procedure were performed, which revealed the lesion to be a germinoma.
  • Chemotherapy using cisplatin, etoposide, vincristine, and cyclophosphamide was initiated on postoperative Day 10.
  • An MR image obtained 10 weeks after surgery and 2 weeks after chemotherapy revealed a significant (> 50%) reduction of the lesion.
  • Radiation therapy was administered at 50.4 Gy to the target and 36 Gy to the periphery.
  • [MeSH-major] Cerebral Ventricle Neoplasms / diagnosis. Endoscopy. Germinoma / diagnosis. Neoplasm Recurrence, Local / diagnosis. Neoplasm Seeding. Pinealoma / diagnosis. Radiotherapy, Conformal. Third Ventricle. Ventriculostomy
  • [MeSH-minor] Adolescent. Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Chemotherapy, Adjuvant. Combined Modality Therapy. Female. Humans. Neurologic Examination. Radiotherapy Planning, Computer-Assisted. Radiotherapy, Adjuvant

  • Genetic Alliance. consumer health - Germinoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17644923.001).
  • [ISSN] 0022-3085
  • [Journal-full-title] Journal of neurosurgery
  • [ISO-abbreviation] J. Neurosurg.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


16. Abe H, Minagawa T, Ishiwara R, Uchigasaki S, Takeda F: [Multiple recurrent cardiac myxomas]. Kyobu Geka; 2009 Mar;62(3):198-201

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Echocardiography revealed new masses in the left atrium and the right ventricle.
  • Both tumors were removed surgically and subsequently treated with adjuvant chemotherapy.
  • [MeSH-major] Heart Neoplasms / surgery. Myxoma / surgery. Neoplasm Recurrence, Local
  • [MeSH-minor] Cardiac Surgical Procedures. Chemotherapy, Adjuvant. Heart Atria. Heart Ventricles. Humans. Male. Middle Aged. Reconstructive Surgical Procedures. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19280949.001).
  • [ISSN] 0021-5252
  • [Journal-full-title] Kyobu geka. The Japanese journal of thoracic surgery
  • [ISO-abbreviation] Kyobu Geka
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


17. Ehata S, Hanyu A, Fujime M, Katsuno Y, Fukunaga E, Goto K, Ishikawa Y, Nomura K, Yokoo H, Shimizu T, Ogata E, Miyazono K, Shimizu K, Imamura T: Ki26894, a novel transforming growth factor-beta type I receptor kinase inhibitor, inhibits in vitro invasion and in vivo bone metastasis of a human breast cancer cell line. Cancer Sci; 2007 Jan;98(1):127-33
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Ki26894, a novel transforming growth factor-beta type I receptor kinase inhibitor, inhibits in vitro invasion and in vivo bone metastasis of a human breast cancer cell line.
  • Use of inhibitors of TGF-beta signaling may thus be a novel strategy for treatment of patients with such cancers.
  • In this study, we investigated the effects of a novel TGF-beta type I receptor (TbetaR-I) kinase inhibitor, Ki26894, on bone metastasis of a highly bone-metastatic variant of human breast cancer MDA-MB-231 cells, termed MDA-MB-231-5a-D (MDA-231-D).
  • X-ray radiography revealed that systemic Ki26894 treatment initiated 1 day before the inoculation of MDA-231-D cells into the left ventricle of BALB/cnu/nu female mice resulted in decreased bone metastasis of breast cancer cells.
  • [MeSH-major] Activin Receptors, Type I / pharmacokinetics. Antineoplastic Agents / pharmacology. Bone Neoplasms / drug therapy. Mammary Neoplasms, Experimental / drug therapy. Mammary Neoplasms, Experimental / pathology. Neoplasm Metastasis / prevention & control. Protein Kinase Inhibitors / pharmacology
  • [MeSH-minor] Animals. Female. Humans. Immunoblotting. In Vitro Techniques. Mice. Neoplasm Invasiveness / prevention & control. Protein-Serine-Threonine Kinases. Receptors, Transforming Growth Factor beta / drug effects. Reverse Transcriptase Polymerase Chain Reaction


18. Gorchakova O, Koch W, Mehilli J, von Beckerath N, Schwaiger M, Schömig A, Kastrati A: PlA polymorphism of the glycoprotein IIIa and efficacy of reperfusion therapy in patients with acute myocardial infarction. Thromb Haemost; 2004 Jan;91(1):141-5
Hazardous Substances Data Bank. TECHNETIUM, ELEMENTAL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] PlA polymorphism of the glycoprotein IIIa and efficacy of reperfusion therapy in patients with acute myocardial infarction.
  • The Pl(A) polymorphism of the platelet glycoprotein IIIa gene is associated with altered platelet function and response to antiplatelet drugs.
  • We sought to assess whether the Pl(A) polymorphism influences myocardial salvage achieved by reperfusion therapy in patients with acute myocardial infarction.
  • Technetium-99m sestamibi was injected before and 1-2 weeks after reperfusion treatment.
  • Clinical follow-up was done up to 18 months after primary treatment.
  • There were no significant differences between Pl( A2) allele carriers and Pl(A1/A1) patients in salvage index (0.4+/-0.50 vs. 0.4+/-0.43, respectively, P=0.48), final infarct size (16.8+/-20.8% vs. 18.4+/-19.1% of left ventricle, respectively, P=0.46) as well as 18-month mortality (8.5% vs.7.1%, respectively, P=0.69).
  • Thus, these findings show that the functional Pl(A) polymorphism of platelet glycoprotein IIIa has no influence on the degree of myocardial salvage achieved by reperfusion therapies in patients with acute myocardial infarction.
  • [MeSH-major] Antigens, Neoplasm / genetics. Integrin beta3 / genetics. Myocardial Infarction / genetics. Myocardial Reperfusion. Polymorphism, Genetic
  • [MeSH-minor] Aged. Alleles. Antibodies, Monoclonal / pharmacology. Blood Platelets / drug effects. Female. Genotype. Humans. Immunoglobulin Fab Fragments / pharmacology. Male. Middle Aged. Polymerase Chain Reaction. Random Allocation. Reperfusion. Technetium / pharmacology

  • MedlinePlus Health Information. consumer health - Heart Attack.
  • Hazardous Substances Data Bank. Abciximab .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 14691579.001).
  • [ISSN] 0340-6245
  • [Journal-full-title] Thrombosis and haemostasis
  • [ISO-abbreviation] Thromb. Haemost.
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article; Randomized Controlled Trial
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antigens, Neoplasm; 0 / ITGB3 protein, human; 0 / Immunoglobulin Fab Fragments; 0 / Integrin beta3; 0 / tumor rejection antigen P815A, mouse; 7440-26-8 / Technetium; X85G7936GV / abciximab
  •  go-up   go-down


19. Katunuma N, Tsuge H, Nukatsuka M, Asao T, Fukushima M: Structure-based design of specific cathepsin inhibitors and their application to protection of bone metastases of cancer cells. Arch Biochem Biophys; 2002 Jan 15;397(2):305-11
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The decalcification during bone absorption is followed by the degradation of type-1 collagen by osteoclastic cathepsins.
  • Tumor-bearing osteoclasts or TNF-alpha-activated osteoclasts secrete large amounts of cysteine proteases, especially procathepsin L, which powerfully degrade type-1 collagen leading to tumor-associated bone absorption and release of bone calcium.
  • The bone pit formations in vitro, which are caused by osteoclasts derived from human bone marrow cells activated by RANKL and M-CSF and also by mice osteoclasts activated by TNF-alpha, are significantly prevented by CLIK-148 treatment.
  • We evaluated the in vivo inhibitory effect of malignant hypercalcemia induced by LJC-1 human mandibular cancer inoculation by CLIK-148 treatment, and the CLIK-148 treatment significantly protected against the tumor-induced hypercalcemia.
  • On the protection of bone metastasis of colon 26 PMF-15 implanted to mouse calvaria, CLIK-148 treatment significantly inhibited calvaria bone absorption (direct metastasis).
  • The CLIK-148 treatment also reduced distant bone metastasis to the femur and tibia of melanoma A375 tumors implanted into the left ventricle of the heart.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Bone Neoplasms / drug therapy. Cathepsins / antagonists & inhibitors. Cysteine Proteinase Inhibitors / therapeutic use. Epoxy Compounds / therapeutic use. Hypercalcemia / drug therapy. Pyridines / therapeutic use
  • [MeSH-minor] Animals. Bone Resorption / drug therapy. Collagen / metabolism. Colonic Neoplasms / drug therapy. Drug Design. Femur / pathology. Humans. Melanoma / drug therapy. Mice. Neoplasm Metastasis

  • Genetic Alliance. consumer health - Bone Cancer.
  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c)2002 Elsevier Science.
  • (PMID = 11795887.001).
  • [ISSN] 0003-9861
  • [Journal-full-title] Archives of biochemistry and biophysics
  • [ISO-abbreviation] Arch. Biochem. Biophys.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / CLIK 148; 0 / Cysteine Proteinase Inhibitors; 0 / Epoxy Compounds; 0 / Pyridines; 9007-34-5 / Collagen; EC 3.4.- / Cathepsins
  •  go-up   go-down


20. Hiraoka K, Zenmyo M, Watari K, Iguchi H, Fotovati A, Kimura YN, Hosoi F, Shoda T, Nagata K, Osada H, Ono M, Kuwano M: Inhibition of bone and muscle metastases of lung cancer cells by a decrease in the number of monocytes/macrophages. Cancer Sci; 2008 Aug;99(8):1595-602
Genetic Alliance. consumer health - Bone Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Treatment with clodronate encapsulated by liposomes (Cl(2)MDP-LIP) has been developed for the depletion of monocytes/macrophages in an animal model.
  • Subcutaneous administration of Cl(2)MDP-LIP markedly reduced the number of monocytes in peripheral blood, resulting in efficient suppression of both bone metastasis and muscle metastasis when lung cancer HARA-B cells were injected into the left cardiac ventricle of mice.
  • Treatment with Cl(2)MDP-LIP significantly reduced the number of macrophages in tumors and the number of osteoclasts in bone marrow, as well as peripheral monocytes in mice harboring lung cancer cells.
  • In contrast, treatment with an osteoclast-targeting antibiotic, reveromycin A, inhibited bone metastasis by lung cancer cells, but not muscle metastasis.
  • Liposome-encapsulated bisphosphonate may modulate metastasis through decreasing the number of monocytes/macrophages in both peripheral blood and the tumor stroma, suggesting that tumor-associated macrophages might be suitable targets for antimetastatic therapy.
  • [MeSH-major] Bone Density Conservation Agents / pharmacology. Clodronic Acid / pharmacology. Macrophages / drug effects. Monocytes / drug effects. Pyrans / pharmacology. Spiro Compounds / pharmacology
  • [MeSH-minor] Animals. Bone Neoplasms / drug therapy. Bone Neoplasms / secondary. Disease Models, Animal. Female. Humans. Lung Neoplasms / drug therapy. Lung Neoplasms / pathology. Mice. Mice, Inbred BALB C. Muscle Neoplasms / drug therapy. Muscle Neoplasms / secondary. Neoplasm Invasiveness

  • Genetic Alliance. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18754872.001).
  • [ISSN] 1349-7006
  • [Journal-full-title] Cancer science
  • [ISO-abbreviation] Cancer Sci.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Bone Density Conservation Agents; 0 / Pyrans; 0 / Spiro Compounds; 0813BZ6866 / Clodronic Acid; 134615-37-5 / reveromycin A
  •  go-up   go-down


21. Khalili P, Arakelian A, Chen G, Plunkett ML, Beck I, Parry GC, Doñate F, Shaw DE, Mazar AP, Rabbani SA: A non-RGD-based integrin binding peptide (ATN-161) blocks breast cancer growth and metastasis in vivo. Mol Cancer Ther; 2006 Sep;5(9):2271-80
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • PURPOSE: Integrins are expressed by numerous tumor types including breast cancer, in which they play a crucial role in tumor growth and metastasis.
  • EXPERIMENTAL DESIGN: MDA-MB-231 human breast cancer cells were inoculated s.c. in the right flank, or cells transfected with green fluorescent protein (MDA-MB-231-GFP) were inoculated into the left ventricle of female BALB/c nu/nu mice, resulting in the development of skeletal metastasis.
  • Tumor volume was determined at weekly intervals and tumor metastasis was evaluated by X-ray, microcomputed tomography, and histology.
  • RESULT: Treatment with ATN-161 caused a significant dose-dependent decrease in tumor volume and either completely blocked or caused a marked decrease in the incidence and number of skeletal as well as soft tissue metastases.
  • This was confirmed histologically as well as radiographically using X-ray and microcomputed tomography.
  • Treatment with ATN-161 resulted in a significant decrease in the expression of phosphorylated mitogen-activated protein kinase, microvessel density, and cell proliferation in tumors grown in vivo.
  • CONCLUSION: These studies show that ATN-161 can block breast cancer growth and metastasis, and provides a rationale for the clinical development of ATN-161 for the treatment of breast cancer.
  • [MeSH-major] Adenocarcinoma / drug therapy. Bone Neoplasms / prevention & control. Bone Neoplasms / secondary. Breast Neoplasms / drug therapy. Oligopeptides / pharmacology
  • [MeSH-minor] Animals. Cell Growth Processes / drug effects. Cell Line, Tumor. Female. Green Fluorescent Proteins / biosynthesis. Green Fluorescent Proteins / genetics. Humans. Mice. Mice, Inbred BALB C. Mice, Nude. Neoplasm Metastasis. Neovascularization, Pathologic / drug therapy. Radiography / instrumentation. Soft Tissue Neoplasms / prevention & control. Soft Tissue Neoplasms / secondary. Transfection. Xenograft Model Antitumor Assays

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • SciCrunch. DrugBank: Data: Chemical .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16985061.001).
  • [ISSN] 1535-7163
  • [Journal-full-title] Molecular cancer therapeutics
  • [ISO-abbreviation] Mol. Cancer Ther.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Oligopeptides; 0 / acetyl-prolyl-histidyl-seryl-cysteinyl-asparaginamide; 147336-22-9 / Green Fluorescent Proteins
  •  go-up   go-down






Advertisement